Year: 2021

– TARA-002 Confirmatory Large-Scale GMP Comparability Complete – – U.S. FDA Cleared the Company’s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End – – Strong Cash, Cash Equivalents, and Marketable Debt Securities of $138.4M as of September 30, 2021 – NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “We have made significant progress advancing our TARA-002 clinical programs in the third quarter, most notably the completion of our confirmatory large-scale GMP comparability work and the clearance of our Investigational New Drug...

VAL-D’OR, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) — Cartier Resources Inc. (TSX-V: ECR) (“Cartier”) is pleased to announce that it has awarded to InnovExplo Inc. (“InnovExplo”) which will work in collaboration with the firm PRB Mining Services Inc., the mandate to prepare a Preliminary Economic Assessment (“PEA”) in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) for its 100% owned Chimo Mine Project situated along the Cadillac-Larder Lake Fault, 45 km east of Val-d’Or. “We are pleased that our Chimo Mine Project has reached this important milestone and believe it will demonstrate the significant potential of this key asset in the rich Val-d’Or mining district” commented Philippe Cloutier, President and CEO of Cartier Resources. Highlights of the Chimo Mine ProjectThe...

WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place from November 10 – 14, 2021 in Washington, D.C. and virtually, and at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 – 14, 2021 in Atlanta, GA and virtually. Kymera is developing selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. STAT3 is a transcription factor activated through...

DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has consistently proven to be more precise at identifying patients who are immunotherapy responders including those who may have been missed by PDL-1 IHC and other biomarkers IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the clinical launch of its DetermaIOTM test. DetermaIO is a proprietary gene expression test that assesses the tumor immune microenvironment (TIME) to predict response to immunotherapy....

DAVIDsTEA is popping up at select malls across the country for a limited time only as of November 2ndKiosk 2021New openings: Holiday Pop-up locations of DAVIDsTEA near you!MONTRÉAL, Nov. 04, 2021 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (Nasdaq:DTEA), a leading tea merchant in North America, is pleased to announce that it is back in key Canadian locations for the holidays! To kick-start the festive season, the brand has deployed six holiday-themed pop-up shops at select locations across the country, bringing holiday cheer and reconnecting with new and past customers, until December 31st. Eager to expand its local presence this holiday season, DAVIDsTEA pop-up shops will feature some of its best-sellers and most popular holiday favourites. The pop-ups will provide tea lovers with the distinctive DAVIDsTEA experience,...

Figure 1Brixton Metals Mineral Claim Holdings MapFigure 2Hog Heaven Project Location MapVANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce an update on the Hog Heaven Project which is currently being operated under a definitive earn-in JV Agreement with Ivanhoe Electric Inc.[1], a privately-owned mineral exploration and development company led by Chairman and CEO, Robert Friedland (see news release dated March 2nd, 2021). The Hog Heaven Project is a high sulphidation epithermal copper-gold-silver project with porphyry potential and historical production located in the state of Montana, USA. HighlightsCompleted a 14,500-meter re-logging program of current and historic drill core Re-sampled...

BOCA RATON, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will participate in the RBC Capital Markets Technology, Internet, Media and Telecommunications Conference on Tuesday, November 16, 2021. Derek Dubner, Chief Executive Officer, and Daniel MacLachlan, Chief Financial Officer, will host virtual 1-on-1 meetings. About red violet® At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including risk mitigation,...

RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022 RP2; Updated monotherapy and combination data with Opdivo (nivolumab) to be presented at SITC this month; Phase 1 protocol amendment expansion to add additional patients with liver metastases filed RP2/3; Detailed Phase 2 clinical development program including patients with liver metastases to be presented in Q1 2022 along with initial RP3 Phase 1 monotherapy data Cash at 30 September of ~$436m with runway into second half of 2024 WOBURN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing...